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Background: Hepatic steatosis is recognized as a major risk factor for liver disease progression and impaired
response to interferon based therapy in chronic hepatitis C (CHC) patients. The mechanism of response to
interferon-alpha (IFN-α) therapy under the condition of hepatic steatosis is unexplored. We investigated the effect
of hepatocellular steatosis on hepatitis C virus (HCV) replication and IFN-α antiviral response in a cell culture model.
Methods: Sub-genomic replicon (S3-GFP) and HCV infected Huh-7.5 cells were cultured with a mixture of saturated
(palmitate) and unsaturated (oleate) long-chain free fatty acids (FFA). Intracytoplasmic fat accumulation in these
cells was visualized by Nile red staining and electron microscopy then quantified by microfluorometry. The effect of
FFA treatment on HCV replication and IFN-α antiviral response was measured by flow cytometric analysis, Renilla
luciferase activity, and real-time RT-PCR.
Results: FFA treatment induced dose dependent hepatocellular steatosis and lipid droplet accumulation in the HCV
replicon cells was confirmed by Nile red staining, microfluorometry, and by electron microscopy. Intracellular fat
accumulation supports replication more in the persistently HCV infected culture than in the sub-genomic replicon
(S3-GFP) cell line. FFA treatment also partially blocked IFN-α response and viral clearance by reducing the
phosphorylation of Stat1 and Stat2 dependent IFN-β promoter activation. We show that FFA treatment induces
endoplasmic reticulum (ER) stress response and down regulates the IFNAR1 chain of the type I IFN receptor leading
to defective Jak-Stat signaling and impaired antiviral response.
Conclusion: These results suggest that intracellular fat accumulation in HCV cell culture induces ER stress, defective
Jak-Stat signaling, and attenuates the antiviral response, thus providing an explanation to the clinical observation
regarding how hepatocellular steatosis influences IFN-α response in CHC.
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Hepatitis C virus (HCV) infection affects an estimated
180 million people worldwide and is one of the major
causes of chronic liver diseases, liver cirrhosis, and hepa-
tocellular carcinoma [1-3]. The standard of care for chro-
nic HCV genotype 1 infection includes a combination of* Correspondence: sdash@tulane.edu
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reproduction in any medium, provided the orinterferon-alpha (IFN-α) , ribavirin and one of the prote-
ase inhibitors (either telaprevir or boceprevir). This
triple combination therapy has greatly improved the sus-
tained antiviral responses among chronic HCV patients.
However, a large percentage of chronic HCV patients
are still unable to clear the infection with this regimen.
The predictors of sustained virological response (SVR)
to interferon based combination therapy have been
linked to host genetic factors IL-28B genotypes, viral
load, viral genotypes, body weight, stage of liver diseases,
obesity, type-2 diabetes mellitus (DM), fibrosis stage and
co-infection with human immunodeficiency virus [4-9].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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virin action has significantly increased due to the availabil-
ity of the HCV cell culture system. We and other groups
have shown that IFN-α efficiently inhibits replication of
HCV in the cell culture model [10-14]. Therefore, the
HCV cell culture model provides an excellent in vitro
model system to assess the contribution of a number of
host related factors in the mechanisms of IFN-α resistance.
A number of clinical studies have reported that over-
weight or obese HCV-infected individuals or those with
steatosis of the liver are at a higher risk for IFN-α non-
responsiveness [15-17]. The prevalence of hepatic stea-
tosis in chronic hepatitis C patients has been reported to
vary between 50-80%, and is associated with excessive al-
cohol drinking, increased body weight, DM and other
metabolic diseases [18]. The increased lipogenesis and
the free fatty acid (FFA) overflow to hepatocytes have
been proposed to be the major cause for hepatic stea-
tosis [19]. Chronic HCV infection also leads to abnor-
malities of lipid metabolism and insulin resistance,
factors that also increase the risk of type-2 DM [16].
There are data supporting the fact that patients with
high body mass index have a lower chance of SVR
[17]. The molecular mechanisms explaining how the
hepatic steatosis and related metabolic liver diseases
reduce the SVR of IFN-α are unknown.
Palmitic and oleic acids are the most abundant FFAs
in liver triglycerides in patients with nonalcoholic fatty
liver disease [20]. This study was carried out to examine
the effect of co-culturing the mixture of these two FFAs
on HCV replication and IFN-α antiviral response using
stable sub-genomic replicon and full-length HCV
infected cell cultures. We show that FFA treatment of
HCV cell culture induces hepatocellular steatosis and
lipid accumulation in a dose dependent manner. Intra-
cellular fat accumulation in HCV cell culture increased
the viral replication and partially blocked the antiviral
response of IFN-α. We present experimental evidence
indicating that intracellular lipid accumulation induces
ER stress response and down regulates the IFNAR1
chain of the type I interferon receptor, leading to the
creation of defective Jak-Stat signaling and impaired
antiviral response of IFN-α against HCV.
Materials and methods
HCV cell culture and chemicals
The stable S3-GFP replicon cell line (HCV2a) was main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 2 mM L-glutamine, sodium pyruvate,
nonessential amino acids, 100 U/mL penicillin, 100 mg/
mL streptomycin, and 10% fetal bovine serum supple-
mented with G-418 (1 μg/mL) [21]. Nile red, sodium
oleate, sodium palmitate, and fatty acid free bovine
serum albumin (BSA) were obtained from SigmaChemical Co., Saint Louis, MO. Recombinant human
IFN-α 2b (Intron A) was purchased from Schering
Plough, Kenilworth, NJ. The Huh-7.5 cell line was
obtained from the laboratory of Charlie Rice (The Rocke-
feller University, New York) and maintained in DMEM
with 10% FBS.
Western blot
Protein lysates from S3-GFP replicon cells were prepared
after treatment with FFAs. Equal amounts of protein
were resolved on SDS-PAGE gels [21]. The antibodies to
Stat1, Stat2, p-Stat1 (Y701), p-Stat2 (Tyr690), p-Jak1
(Tyr1022/1023), p-Tyk2 (Tyr1054/1055), total eIF2α,
p-eIF2α (Ser51), beta-actin, IRE1-alpha, PKR, PERK, BIP,
SOCS-3, anti-mouse IgG, and anti-rabbit IgG HRP-
linked antibody were purchased from Cell Signaling,
Beverly, MA. Antibodies to interferon alpha-receptor 2
(IFNAR2) and p-IFNAR1 were purchased from Santa
Cruz Biotechnologies, Santa Cruz, CA. The antibody to
p-PKR (pT446) was obtained from Epitomics, Burlin-
game, CA. A mouse monoclonal antibody to IFNAR1
(GB8) was kindly provided by Biogen Idec Inc., Cam-
bridge, MA, USA.
Fatty acid treatment
We used a formulation of FFA mixture at a 2:1 ratio of
oleate to palmitate that mimics benign chronic steatosis
with low toxicity described by other investigators [22-25].
Briefly, 100 mM palmitate (Sigma catalog No. P-0500)
and 100 mM Oleate (Sigma Catalog No. 0–7501) stocks
were prepared in 0.1 M NaOH at 70°C and filter steri-
lized. Five percent (w/v) FFA-free BSA solution was pre-
pared in double distilled water and filter sterilized. A
5 mM stock solution for each fatty acid was prepared in
5% BSA solution in distilled water at 60°C then the mix-
ture was cooled to room temperature. These two FFAs
were first mixed together in growth medium in a sterile
environment under laminar flow so that the final concen-
tration of FFA was 1 mM and BSA was 1%. S3-GFP cells
were cultured in 10-cm dishes to 80-85% confluence and
co-cultured with different concentrations of FFA for 24
hours to induce steatosis. At indicated time points, the
cells were washed in PBS and cultured in regular growth
medium containing 10% FBS.
Nile red staining and microfluorometry
Intracellular fat accumulation in the HCV cell culture
was determined by Nile red staining as described
[22]. Briefly, hepatocyte monolayers were washed
twice with phosphate-buffered saline (PBS) and incu-
bated for 15 minutes with Nile red solution at a con-
centration of 1 mg/mL in PBS at 37°C. After this
treatment, the cell monolayer was washed with PBS
and counterstained with a nuclear staining Hoechst
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concentration of 10 μg/mL prepared in PBS. Cells
were then examined under a fluorescence microscope
as described previously [21]. The intracellular fat con-
tent was quantitated using a microfluorometer (exci-
tation 488 nm and emission 550 nm).
Electron microscopy
Intracellular fat accumulation in the FFA treated cells
was also confirmed by electron microscopy using a
standard protocol [26].
MTT assay
The effect of FFA treatment on the cell proliferation was
measured using a MTT colorimetric assay [27]. The assay
uses a tetrazolium compound (3-[4, 5-dimethylthiazol-2-
yl]-2, 5-diphenyl tetrazolium bromide) (M5655, Sigma-
Aldrich, St Louis, MO), which is reduced intracellularly
to formazan by a mitochondrial dehydrogenase enzyme.
The percentage of cell viability was determined by com-
parison with untreated controls.
Flow cytometry
The effect of FFA treatment on HCV replication and
IFNAR1 expression was measured by flow analysis as
described previously [21]. Briefly, S3-GFP replicon cells
with or without FFA treatment were collected 24 h post-
treatment. Intracellular GFP expression was quantified
using a flow cytometer (BD LSR II, BD Biosciences). For
the analysis of IFNAR1 expression, Huh-7 cells were
treated similarly and processed using an IFNAR1 anti-
body (Epitomics, Burlingame, CA), as per the supplier’s
protocol, with the secondary antibody (Alexa Fluor 488-
labeled) procured from Invitrogen, CA. Histograms were
generated using WinMDI version 2.8 software (Scripps.
edu).
Real-time RT-PCR
Total RNA was isolated from the cells using the GITC
method and real-time RT-PCR was carried out as
described [28].
Infectious cell culture model for HCV with a luciferase
reporter
Full-length chimeric virus encoding Renilla luciferase
(pJFH-ΔV3-Rluc) was kindly provided by Curt H Hage-
dorn, University of Utah School of Medicine, Salt Lake
City [29]. The pJFH-ΔV3-Rluc plasmid was linearized
with Xba I, extracted with phenol /chloroform and pre-
cipitated with ethanol. HCV-RNA transcripts were pre-
pared in vitro by using T7 RNA polymerase. 1 × 107
Huh-7.5 cells were electroporated with 20 μg of HCV
RNA. Transfected cells were cultured in complete
DMEM. Infectivity assay was carried out using thesupernatants 96 hr post-transfection. Briefly, Huh-7.5
cells were infected with JFH-ΔV3-Rluc virus (MOI 0.1)
overnight. On the following day, the infected culture was
washed with PBS and then incubated with 10 mL of
DMEM with 10% FBS. Infected Huh-7.5 cells were cul-
tured long-term by splitting at a 1:10 ratio at five-day
intervals. Replication of HCV in the infected cell culture
at each interval was confirmed by measuring the Renilla
luciferase activity or the HCV RNA level by RT-qPCR.
Renilla luciferase activity was measured in 5μL cell lysate
using a luciferase assay kit (Promega) and total protein
was measured using the Bradford assay.Luciferase assay
The effect of FFA treatment on Jak-Stat signaling and
IFN-β (pISRE-Firefly luciferase) promoter activity was
examined using a published protocol (21). The ATF6-
Luc activity was measured by co-transfecting 0.5 μg of
p5XATF6GL3 (Addgene, Cambridge, MA) DNA along
with pRL-TK plasmid (0.5 μg) in S3-GFP cells 24 h prior
to FFA treatment. Cell lysates were prepared 24 h post
FFA treatment and the Firefly luciferase values were nor-
malized to the Renilla luciferase values.Immunohistochemical staining for HCV-core protein
Infected Huh-7.5 cells were mounted onto a glass slide
via the cytospin method. The cells were washed twice
with 10 mM PBS pH 7.4 (Sigma-Aldrich, St Louis, MO)
for 5 minutes. The cells were fixed in chilled acetone for
15 minutes and then permeabilized by treatment with
Reveal Decloaker RTU (Biocare Medical, RV 100) for 25
minutes at boiling point. Slides were then cooled down
at room temperature for 25 minutes. Blocking was per-
formed utilizing Background Sniper (Biocare Medical,
BS966) for 10 minute at room temperature. The cells
were incubated with monoclonal anti-core antibody
(Thermo Scientific, Pierce hepatitis C virus core antigen
specific mouse monoclonal antibody, Ma1-080) at 1:200
diluted with Da Vinci Green Diluent (Biocare Medical,
PD900) for 1 hour at room temperature. Following the
primary antibody incubation, the cells were washed 3
times in Tris Buffered Saline (pH 8.0), and incubated
with MACH 4 mouse probe (Biocare Medical, UP534)
for 10 minutes. After mouse probe treated, the cells
were incubated with MACH4 HRP Polymer (Biocare
Medical, MRH534) for 30 minutes, and the cells were
washed with TBS 3 times. Next, the cells were treated
with diaminobenzidine (DAB) chromogen (Dako Cyto-
mation, Carpinteria, CA) for 5 minutes. The slides were
counterstained with hematoxylin for 30 seconds and
Tacha’s bluing Solution (Biocare Medical, HTBLU) for
30 seconds, dehydrated, mounted and observed by light
microscopy.
Figure 1 FFA treatment induces hepatocellular steatosis in HCV replicon cells. S3-GFP cells in culture were treated with increasing
concentrations of Oleate/Palmitate (2: 1 ratio) and hepatocellular steatosis due to an intracellular fat accumulation was characterized by a number
of methods. (A) Fluorescence microscopy showing concentration dependent hepatocellular steatosis in S3-GFP cells 24 h post treatment by Nile
Red staining (yellow) and nuclear staining (blue). The images were taken at 40× magnifications. (B) Microfluorometer analysis of intracellular fat
accumulation in S3-GFP cells 24 h after FFA treatment. The values are expressed as fold change compared to untreated cells, *P <0.001, Student
t test. (C) MTT assay showing the effect of intracellular fat accumulation (dose-dependent) on cellular cytotoxicity of S3-GFP cells in culture. Cell
viability was expressed as % of untreated. (D) MTT assay showing cell viability over time (h) for concentrations of FFA up to 0.5 mM. (E) Electron
micrograph of FFA-treated (0.5 mM) S3-GFP cells showing intracellular lipid droplet accumulation. (i) Untreated cells, (ii) FFA-treated cells,
4000×magnification, and (iii) 7000× magnification showing fat droplets in the endoplasmic reticulum (ER) (black arrow).
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Microfluorometry assay results, ISRE, ATF6 (activating
transcription factor 6), and HCV (pJFH-ΔV3-Rluc) luci-
ferase activity, real time RT-PCR and FACS analysis were
compared for significance using the Student’s t test.
P values less than 0.05 were considered significant.
Results
FFA treatment induces cellular steatosis in HCV cell culture
Oleate (unsaturated) and palmitate (saturated) fatty acids
were mixed at a ratio of 2:1 and directly added to the cell
culture medium supplemented with 1% BSA to inducesteatosis in S3-GFP cells in culture. The concentration of
saturated fatty acids to nonsaturated fatty acids used in our
study is comparable to the pathological range of human
non-alcoholic fatty liver disease. First, S3-GFP cells were
cultured with increasing concentrations of FFA and hepato-
cellular steatosis was confirmed by fluorescence microscopy
after Nile red staining. Representative pictures show that
FFA treatment resulted in dose-dependent intracellular
lipid accumulation in the HCV replicon cells that can be
visualized by fluorescence microscopy (Figure 1A). S3-GFP
cells treated with an equimolar concentration of BSA car-
rier protein were used as a control. Results of microscopic
Figure 2 Effect of hepatocellular steatosis on HCV RNA replication in S3-GFP replicon cell line. S3-GFP replicon cells were cultured with
different concentrations of FFA in 1% BSA for 5 days. Untreated cells received only 1% BSA. (A) The HCV-GFP expression was measured by using
fluorescence microscopy. (B). Quantification of GFP expression of S3-GFP in replicon cells by flow analysis. The number indicates the mean
fluorescence of GFP-positive cells. (C). Intracellular HCV RNA levels in S3-GFP replicon cells were measured by real time RT-PCR.
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HCV cell cultures were quantified by microfluorometry
(Figure 1B). The concentration-dependent toxic effect of
FFA treatment in the HCV cell culture was determined by
using the MTT assay (Figure 1C) indicating that increasing
concentrations of FFA were toxic to the cells. MTT assay
results showed that the FFA mixture caused cellular toxicity
at and above 1 mM. The long-term stability and toxicity of
intracellular lipid droplet accumulation in the FFA trea-
ted HCV cell culture was also examined in a kinetic study
(Figure 1D) suggesting that FFA up to 0.1 to 0.5 mM can
induce a fairly high level of hepatocellular steatosis in
100% of the cells in culture without causing apparent
toxicity. Electron microscopic studies confirmed that S3-
GFP cells cultured with FFA developed intracytoplasmic
accumulation of lipid droplets in the vicinity of the ER
(Figure 1E). Based on these results, hepatocellular steato-
sis in HCV cell culture was carried out using the highly
viable concentrations of FFA (10–100 μM) to determine
its impact on virus replication and IFN-α antiviral
response.Intracellular fat accumulation increases HCV RNA replication
To determine whether intracellular fat accumulation
plays a role in modulating HCV RNA replication, we
cultured S3-GFP replicon cells with different concen-
trations of FFA (25-100 μM). The expression of HCV
GFP fusion protein was monitored using fluorescence
microscopy (Figure 2A), and then quantified by flow
cytometric analysis (Figure 2B). The mean fluo-
rescence of GFP-positive cells following FFA treat-
ment for 5-days was increased from 69.1% to 76.8%
as compared to cells treated with BSA (Figure 2B).
The increase in HCV RNA levels in the S3-GFP cells
after treatment with increasing concentration of FFA
after 5-days was measured by real time RT-PCR
(Figure 2C). The replicon based HCV cell culture
model lacks the structural protein and this culture
does not produce an infectious virus, therefore the ef-
fect of FFA treatment on HCV replication was exam-
ined using a persistently infected HCV cell culture
system. The replication of HCV in the infected Huh-
7.5 cells after FFA treatment was measured using a
Figure 3 Effect of hepatocellular steatosis on HCV RNA replication in the infected Huh 7.5 cells. Huh-7.5 cells were infected overnight
with HCV chimeric virus encoding Renilla luciferase (pJFH-ΔV3-Rluc). Infected Huh-7.5 cells were cultured long-term in growth media by splitting
at a 1:10 ratio at five days intervals. (A). HCV-Renilla luciferase activity of infected Huh-7.5 cells cultured in the presence FFA for 72 hrs. The values
in the y-axis represent the normalized Renilla luciferase values per one μg of total protein. The X-axis shows the different concentrations of FFA.
(B). Effect of long-term culture FFA on HCV replication. HCV infected cells were cultured in the presence of 100 μM of FFA for 5, 10 and 15 days,
the level of HCV RNA was measured by luciferase assay. The statistical significance was determined by paired T-test, the stars indicate a p value
<0.05. (C). HCV infected cells were cultured in the presence of 100 μM concentrations of FFA for 5, 10 and 15 days. HCV replication was
measured by luciferase assay. The statistical significance was determined by paired T-test, the stars indicate a p value <0.05. (D)
Immunohistochemical staining for HCV core antigen in the infected Huh 7.5 cells in the presence of different concentrations of FAA after 15 days.
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cell culture derived virus (MOI of 0.1) by overnight
incubation then maintained in a long-term culture by
splitting at 1:10 ratio. The effect of the long-term and
short-term culture of FFA on HCV replication was
measured. Initially, we determined the dose depen-
dent effect of FFA treatment on HCV replication in
the infected culture short term over 72 hours. The
results indicate intracellular fat accumulation in the
infected cell culture which resulted in a dose de-
pendent increase in HCV replication measured by
Renilla luciferase activity (Figure 3A). A second set of
experiments was performed to determine the effect of
long-term co-culture of FFA on HCV replication in
the infected cell culture. For this purpose, persistentlyinfected cells were cultured with the FFA for 5, 10 and
15 days then HCV replication in the culture with or
without FFA treatment was measured by Renilla lucifer-
ase activity. Results of this experiment show a statistically
significant increase in the HCV replication with a con-
centration of 100 μM of FFA (Figure 3B &C). The effect
of FFA treatment on HCV replication in the infected
Huh-7.5 cells was also confirmed by immunostaining for
core protein. Results shown in Figure 3D indicate that
HCV core immunostaining of persistently infected Huh-
7.5 cells that had been cultured with the FFA for 15 days
show intense core staining as compared to those without
FFA treatment. Taken together our results indicate that
long-term culture of FFA with infected cells led to an
increased HCV replication.
Figure 4 FFA treatment blocks the antiviral response of IFN-α against HCV. S3-GFP and infected Huh-7.5 cells were cultured with FFA for
5 days and then treated with IFN-α for 72 hours. (A) The antiviral effect of IFN-α with and without FFA treatment measured by real-time RT-PCR
in S3-GFP replicon cells. *P< 0.01, **P < 0.001 , Student t test. (B) Renilla luciferse activity showing the antiviral effect of IFN-α in the infected Huh-
7.5 cells co-cultured with increasing concentration of FFA. The values are normalized with total protein. (C) Luciferase activity showing the dose
dependent antiviral effect of IFN-α blocked by FFA treatment (100 μM) in the infected Huh-7.5 cells. The values in the y-axis represent the values
(RLU) normalized per μg of protein lysates. The values in the x-axis represent the different concentrations of IFN-α (IU/ml).
Gunduz et al. Virology Journal 2012, 9:143 Page 7 of 12
http://www.virologyj.com/content/9/1/143Intracellular lipid accumulation blocks IFN-α antiviral
response against HCV
We tested whether intracellular lipid droplet accumula-
tion affected IFN-α responsiveness to HCV replication
using both a replicon and an infected cell culture model.
S3-GFP replicon cell line was cultured in growth
medium with or without FFA for 5 days, after which
they were treated with IFN-α for an additional 72 h.
S3-GFP cells were also co-cultured with FFA while trea-
ted with IFN-α. The titer of HCV RNA in the replicon
culture was quantified using a real-time RT-PCR assay
indicating that FFA treatment partially blocks the IFN-α
antiviral effect against HCV in a concentration depen-
dent manner (Figure 4A). The effect of FFA treatment on
the IFN-α antiviral response was confirmed using a per-
sistently infected HCV cell culture model. Infected Huh-7.5
cells were co-cultured with different concentrations of
FFA (0–100 μM) then for 5-days after that, the cultures
were treated with IFN-α for 72 h. Replication of HCV in
the infected cell culture model was examined by Renillaluciferase assay. Results shown in Figure 4B indicate that
FFA treatment blocked IFN-antiviral response in a dose
dependent manner. Infected cells treated with FFA show
a dose dependent increase in Renila luciferase activity.
The concentration dependent IFN-α antiviral effect
against HCV in the infected cell culture was examined in
the presence and absence of 100 μM FFA treatment
(Figure 4C). In summary, our results support that FFA
treatment blocked antiviral action of IFN-α in replicon
and infected cell culture. The results are statistically
significant.
FFA induces ER stress to down regulate IFNAR1 and
blocks Jak-Stat signaling
To find an explanation for why S3-GFP replicon cells
that were cultured with FFA showed an impaired IFN-α
antiviral effect, we examined the ER stress pathway. Re-
cent published reports suggest that FFA treatment
induces an ER stress response [30]. Therefore, the activa-
tion of three independent ER stress pathways including
Figure 5 FFA treatment induces an ER stress response in S3-GFP replicon cells. (A) ATF-6 firefly luciferase activity was measured in S3-GFP
cells treated with different concentrations of FFA for 24 h. 24 h post transfection, luciferase activity was measured and values are expressed as
fold induction of control. *P< 0.05, Student t test. (B) Western blot analysis showing that different concentration of FFA induces BIP, IRE1-α,
phospho PKR, phospho eIF2α, and SOCS3 in S3-GFP replicons. β-actin levels were used as loading controls.
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reticulum eIF2a kinase), IRE1 (inositol requiring enzyme
1), and ATF6 (activating transcription factor 6) were
examined [31]. Results shown in Figure 5A indicated that
ATF6-firefly luciferase was activated in a dose-dependent
manner in FFA-treated S3-GFP cells compared to un-
treated cells. FFA treatment of S3-GFP cells induced the
ER stress related markers BIP, IRE1-α, and p-eIF2α
(Figure 5B). The levels of other kinases like PERK and
PKR did not alter with FFA treatment. FFA treatment
also increased SOCS3 (suppressor of cytokine signaling
3) levels. To explain the potential mechanisms that con-
nect the ER stress response to defective Jak-Stat signal-
ing, we examined the cell surface expression of IFNAR1,
which is a known target of ER stress mechanisms. The
expression level of IFNAR1 in S3-GFP replicon cells with
or without FFA treatment was examined by Western blot
analysis and flow cytometry. Results shown in Figure 6,
indicate that FFA treatment resulted in reduced expres-
sion of IFNAR1 but not of IFNAR2. We then examined
the potential effect of ER stress response of FFA on IFN-
induced Jak-Stat signaling by measuring phosphorylation
of downstream proteins including IFNAR1, Jak1, Tyk2,
Stat1, and Stat2 by Western blot analysis (Figure 6A).
Tyk2 phosphorylation was affected significantly as this is
dependent on IFNAR1 expression, but phosphorylation
of pJak1 was unaltered. Intracellular Jak-Stat signaling in
FFA-treated cells was also examined using a firefly luci-
ferase reporter plasmid driven by the IFN-β promoter.
ISRE-Luc promoter activity was significantly affected by
FFA treatment (Figure 6B). The histogram of IFNAR1
cell surface expression showed a change in the peak (shiftto left) of FFA-treated cells (Figure 6C) and the mean
fluorescence intensity (MFI) for FFA-treated cells de-
creased at 0.2 and 0.5 mM FFA. These results suggest that
FFA treatment blocks IFN-α mediated activation of IFN-β
promoter activity in S3-GFP cells and thus impairment of
antiviral action.
Discussion
The standard of care for chronic HCV genotype 1 infec-
tion includes IFN-α plus ribavirin along with one of the
protease inhibitors. However, results of clinical studies
indicate that the sustained virologic response of this
combination therapy is impaired by viral and host
related factors. Viral factors play an important role in
the treatment response since patients infected with HCV
genotype 1 show poor response as compared to geno-
type 2 and 3 [32,33]. In addition to virus genotype, sev-
eral host-related factors can also affect the outcome of
the antiviral therapy including viral load, presence of cir-
rhosis, age, race, and metabolic diseases such as obesity
and diabetes [34,35]. Obesity is a risk factor resulting in
a poor treatment response to both pegylated interferon
and pegylated interferon in combination with ribavirin
[15-17]. Hepatic steatosis can develop secondary to
obesity, DM, alcohol abuse, protein malnutrition, carbo-
hydrate overload, and chronic HCV infection [36]. Hep-
atic steatosis is also a common histopathological feature
of chronic HCV infection that is found in 30-70% of
patients [37,38]. There are reports indicating that HCV
infection induces the development of hepatocellular
steatosis by blocking the release of very low-density lipo-
protein (VLDL) particles from the liver to the circulation
Figure 6 FFA treatment of S3-GFP replicon cell culture blocks IFN-α induced Jak-Stat signaling. (A) Western blot analysis of Jak-Stat
signaling proteins were done in S3-GFP cells cultured with different concentration of FFA for 24 h and then treated with 1000 IU/mL IFN-α for 30
minutes. β-actin levels were used as loading controls. (B) FFA treatment blocks IFN-α-induced ISRE-firefly luciferase activity. S3-GFP cells were
transfected with 1 μg of pISRE-luciferase plasmid and then cultured with FFA for 24 h. Cells were then treated with 1000 IU/mL IFN-α. 24 h post-
transfection, IFN-β promoter activity in the presence and absence of FFA treatment was measured. *P< 0.05 (1 tail), Student t test. (C) Flow
cytometric analysis of IFNAR1 expression in Huh-7 cells treated with or without FFA. The left panel shows a histogram of IFNAR1 expression with
FFA (0.5 mM) treatment for 24 h shifted to the left (red line). The right panel shows the mean fluorescence intensity (MFI) of the IFNAR1 signal.
The flow cytometry plot is representative of three separate experiments, while the MFI values shown are an average (±SD) of these experiments.
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that the presence of hepatic steatosis in patients with
chronic HCV infection affects liver disease progression,
pathogenesis, and treatment response [39-43]. The mech-
anisms of the impaired response to interferon-based ther-
apy in the condition of hepatic steatosis are not clearly
understood.
We took advantage of the HCV cell culture system
established in a liver-derived cell line to study the
mechanisms of IFN-α antiviral response in the pres-
ence or absence of FFAs. Hepatocellular steatosis was
induced in HCV replicon cells with a mixture of satu-
rated and non-statured FFAs. Other investigators have
used this FFA cocktail to study the pathogenic mech-
anism of hepatic steatosis in cell culture. Our results
support that FFA treatment can induce steatosis in
HCV replicon cells in a dose-dependent manner.
High dose FFA treatment in HCV cell culture leads
to increased cell toxicity and cell death by apoptosis
as reported by others [23,30]. We show that the FFA
at 10–100 μM range increased HCV replication inthe infected cell culture supporting data published
previously [44]. Our results suggest that intracellular
fat accumulation partially blocks IFN antiviral action
and viral clearance in replicon and infected cell cul-
ture. Published reports from our laboratory and
others indicate that cellular Jak-Stat signaling is crit-
ical for the successful antiviral response of IFN-α
against HCV [45]. Our results provide evidence sup-
porting that FFA treatment of HCV cell culture
induces an ER stress response that blocks cellular
Jak-Stat signaling by down regulating IFNAR1. As
a result, IFN-α induced Stat1, Stat2 phosphorylation,
and IFN-β promoter activity was attenuated. Studies by
other laboratories, including ours, have shown that ER
stress is correlated well with down regulation of
IFNAR1 in cell culture models [45-47]. We propose that
future studies should be conducted to determine if at-
tenuating the ER-stress response by pharmacological
inhibitors or siRNA knockdown improves the antiviral
response of IFN-α in the condition of hepatic steatosis
by retained expression of IFNAR1.
Figure 7 Schematic representation showing that intracellular lipid droplet accumulation affects Jak-Stat signaling by two possible
mechanisms. (i) Intracellular fat accumulation induces the ER stress related proteins ATF-6, BIP, IRE1-α, and this causes phophorylation of eIF2 α
which leads to the down regulation of IFNAR1 expression. The reduced expression of IFNAR1 affects IFN-α binding, Jak-Stat signaling, and
downstream antiviral responses. IFN-α binds to its cell surface receptor that activates Jak1 and Tyk2 phosphorylation. The activation of Jak1 and Tyk2
is required for the Stat1 and Stat2 phosphorylation. pStat1 and pStat2 bind to IRF9 to form a complex that translocates to the nucleus to induce
IFN-stimulated gene expression. (ii) We show here that FFA treatment induces SOCS3 that also inhibits the phosphorylation of Stat1 and Stat2.
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planation as to the mechanism by which chronic HCV
patients with fatty liver show an impaired response to
IFN and ribavirin treatment. In regards to our findings,
we propose a model that chronic HCV patients
with steatosis have increased lipid droplets in hepato-
cytes that block interferon-dependent Jak-Stat signal-
ing (Figure 7). Our results are also supported by a
number of studies where the role of IFNAR1 expression
has been correlated with the response to IFN-α therapy
in chronic hepatitis C (48–52). The studies conducted by
Taniguchi et al., [48] indicate that high intrahepatic
mRNA levels of IFNAR1 among chronic HCV 1b
patients before treatment is associated with a favorable
response to IFN therapy. Another study by Katsumi et al.
[49] reported that the expression rate of IFNAR1 and
IFNAR2 were significantly higher in responders than
non-responders. Fujiwara et al. [50] have conducted a
study where the expression of IFNAR1 receptor and re-
sponse to interferon therapy was examined in chronic
hepatitis C patients. They found the IFNAR2 expressionlevel in the liver is predictive of the response to IFN-α
treatment in chronic hepatitis C patients. A study by
Meng et al. [51] also examined the expression of IFN-α
and β receptor in the liver of patients with chronic hepa-
titis C who are IFN responders and nonresponders. The
authors found that the expression of the interferon re-
ceptor was more obvious in the IFN-α treatment respon-
sive group than in the non-responsive group. Welzel
et al. [52] have analyzed the relationship between variants
in the IFN-α pathway and SVR among participants in the
hepatitis C antiviral long-term treatment against the cir-
rhosis (HALT-C) trial. They found statistical significance
in the IFNAR1 expression and that the IFNAR2 expres-
sion is associated with a response to antiviral therapy of
chronic HCV patients. In addition to this, a number of
studies have provided evidence suggesting that other
mechanisms may be involved in the impaired response of
IFN-α in obese patients. For example, Walch et al. [17]
found that increased expression of SOCS3 protein is
associated with non-response to IFN-α therapy. These
investigators proposed that increased SOCS3 expression
Gunduz et al. Virology Journal 2012, 9:143 Page 11 of 12
http://www.virologyj.com/content/9/1/143also blocks tyrosine phosphorylation of Stat1 in response
to IFN-α stimulation. We also found that SOCS3 levels
are increased but SOCS1 are not increased (data not
shown) in replicon cells treated with FFA. The involve-
ment of SOCS3 is also another possible mechanism for
how the intracellular lipid alters Jak-Stat signaling. These
in vitro findings suggest that FFA-induced ER stress and
SOCS3 levels are the two major targets that play a role in
reducing Jak-Stat signaling and impaired antiviral re-
sponse of IFN-α in FFA-treated cells.
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